Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis - PubMed
5 days ago
- #Janus kinase inhibitors
- #ulcerative colitis
- #5-aminosalicylic acid
- Study evaluates if 5-aminosalicylic acid (5-ASA) affects clinical remission in UC patients on Janus kinase inhibitors (JAKi).
- Retrospective, multicenter cohort study included 633 UC patients on tofacitinib, upadacitinib, or filgotinib.
- 476 patients received 5-ASA, 151 did not; remission rates at week 48 were similar (81.3% vs. 77.0%).
- Adjusted hazard ratio for 5-ASA vs. no 5-ASA was 1.12 (95% CI 0.91-1.37, P = 0.519).
- Concomitant 5-ASA does not significantly influence time to clinical remission in UC patients treated with JAKi.